NEW YORK (GenomeWeb News) – Fluidigm today announced its collaboration with Novartis to develop a non-invasive fetal diagnostic test has ended.

The collaboration ended on May 1, when Novartis chose not to exercise an option to exclusively license Fluidigm's digital PCR technology. Fluidgm added that it successfully achieved all of its technical feasibility milestones in the first phase of the collaboration and received all milestone payments.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: transcript patterns in drug-resistant cancer cells, function of high-altitude adaption gene, and more.

Monitoring gene expression changes could help sniff out athletes using performance-enhancing drugs, New Scientist says.

The University of Southern California lodges a cross-complaint in its legal dispute with the University of California, San Diego, over a large Alzheimer's disease project.

In PLOS this week: gene fusion in premature ovarian failure, population patterns in the Franciscana dolphin, and more.